These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 11188936

  • 1. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
    Bengio R, Narbaitz M, Palacios F, Scolnik M, Sarmiento M.
    Medicina (B Aires); 2000; 60 Suppl 2():71-6. PubMed ID: 11188936
    [Abstract] [Full Text] [Related]

  • 2. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O, Tomová A, Kusenda J, Gyárfás J.
    Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
    [Abstract] [Full Text] [Related]

  • 3. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
    Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, Cassileth PA, Habermann T, Grever M, Rowe JM, Peterson LC.
    Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
    [Abstract] [Full Text] [Related]

  • 4. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
    Konwalinka G, Schirmer M, Hilbe W, Fend F, Geisen F, Knoblechner A, Petzer A, Thaler J.
    Blood Cells Mol Dis; 1995 Jul; 21(2):142-51. PubMed ID: 8846043
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Rucińska M, Machaczka M, Załuska A, Skotnicki AB.
    Przegl Lek; 1998 Jul; 55(7-8):400-6. PubMed ID: 10021885
    [Abstract] [Full Text] [Related]

  • 8. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR, Wang H, Chang Y, Cheng YF, Fu JY, Zhang LP, Liu GL, Chen SS.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [Abstract] [Full Text] [Related]

  • 9. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine.
    Wheaton S, Tallman MS, Hakimian D, Peterson L.
    Blood; 1996 Feb 15; 87(4):1556-60. PubMed ID: 8608247
    [Abstract] [Full Text] [Related]

  • 10. Minimal residual disease, its detection and significance in hairy-cell leukemia.
    Zák P, Chrobák L, Dĕdic K.
    Acta Medica (Hradec Kralove); 1999 Feb 15; 42(3):85-8. PubMed ID: 10677893
    [Abstract] [Full Text] [Related]

  • 11. The diagnosis of hairy cell leukemia can be established by flow cytometric analysis of peripheral blood, even in patients with low levels of circulating malignant cells.
    Cornfield DB, Mitchell Nelson DM, Rimsza LM, Moller-Patti D, Braylan RC.
    Am J Hematol; 2001 Aug 15; 67(4):223-6. PubMed ID: 11443633
    [Abstract] [Full Text] [Related]

  • 12. Rituximab as treatment for minimal residual disease in hairy cell leukaemia.
    Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, Petrini M.
    Eur J Haematol; 2004 Dec 15; 73(6):412-7. PubMed ID: 15522063
    [Abstract] [Full Text] [Related]

  • 13. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G.
    J Clin Oncol; 2009 Nov 01; 27(31):5168-74. PubMed ID: 19805690
    [Abstract] [Full Text] [Related]

  • 14. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
    Cai JY, Tang YJ, Jiang LM, Pan C, Chen J, Tang JY.
    Pediatr Blood Cancer; 2007 Dec 01; 49(7):952-7. PubMed ID: 17514736
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Application of triple-color flow cytometry for minimal residual disease detection in acute B-lymphoblastic leukemia].
    Chen T, Zhu Y, Zhou X, Wang Y, Ying D.
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jan 01; 22(1):20-3. PubMed ID: 11877045
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A, Gillis D, Lewis I.
    Am J Clin Pathol; 2009 Jan 01; 131(1):16-26. PubMed ID: 19095561
    [Abstract] [Full Text] [Related]

  • 20. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A, Gillis D, Lewis I.
    Cytometry B Clin Cytom; 2009 Mar 01; 76(2):91-101. PubMed ID: 18727068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.